Prime Medicine ($PRME) Stock Forecast: Down 7.7% Today

What is Prime Medicine?

PRME is a biotech company specializing in Prime Editing treatments for genetic diseases like Cystic Fibrosis. The overall market for biotech stocks has been volatile recently due to regulatory concerns and funding news.

Why is Prime Medicine going down?

PRME stock is down 7.7% on Jul 16, 2025 13:40

• The additional funding of up to $24 million from the Cystic Fibrosis Foundation is positive news for PRME, indicating confidence in their Prime Editing treatments for Cystic Fibrosis.
• However, the market may have reacted bearishly due to concerns about potential dilution from the new funding, leading to profit-taking by investors.
• Investors might also be cautious about the timeline for the development of Prime Editors for Cystic Fibrosis, leading to a short-term bearish sentiment in the stock.

PRME Price Chart

PRME Technical Analysis

PRME News

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis ( CF ) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation ...

https://www.globenewswire.com/news-release/2025/07/16/3116255/0/en/Prime-Medicine-Announces-Additional-Funding-of-Up-to-24-Million-from-the-Cystic-Fibrosis-Foundation-to-Advance-Prime-Editing-Treatments-for-Cystic-Fibrosis.html

Trending Today

XRP ($XRP) Crypto Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Up 7.2% Today

QuantumScape Corp. ($QS) Stock Forecast: Up 5.1% Today

Unity Software ($U) Stock Forecast: Up 16.1% Today

Roblox Corp ($RBLX) Stock Forecast: Up 6.8% Today

Global Payments Inc. ($GPN) Stock Forecast: Up 5.1% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 5.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 6.2% Today

Johnson & Johnson ($JNJ) Stock Forecast: Up 5.9% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 14.8% Today

Prime Medicine Price History

30.08.2024 - PRME Stock was down 9.9%

• PRME stock experienced a bearish movement despite positive news and collaborations with Bristol Myers Squibb, indicating a possible sell-off by investors.
• The market may have reacted negatively to the news of a strategic research collaboration and license agreement with Bristol Myers Squibb, possibly due to concerns about the financial terms of the deal.
• Despite unveiling a strategically focused pipeline and positive developments in cell therapy, investors might have been disappointed with the lack of immediate revenue-generating opportunities, leading to the bearish movement in PRME stock.
• The overall market sentiment and broader industry trends could have also influenced the bearish movement in PRME stock, despite the company's positive announcements.

14.03.2025 - PRME Stock was down 5.0%

• The bearish movement in Prime Medicine's stock today could be attributed to an influential investment firm offloading shares in the company, as part of their recent notable trades.
• The selling pressure from a well-known fund, which sold a significant number of shares in Prime Medicine, likely contributed to the downward pressure on the stock price.
• Investors may have reacted to the news of the reduction in exposure to Prime Medicine, leading to a bearish sentiment in the market for the stock.

02.09.2024 - PRME Stock was down 10.8%

• PRME stock rose by 11.8% due to a collaboration announcement with Bristol Myers Squibb for the development of T-cell therapies.
• Despite positive developments, PRME faced a bearish trend, possibly due to profit-taking by investors after a recent sharp rise in stock price.
• The overall market sentiment was slightly lower with the Dow Jones index falling around 0.1%, which might have contributed to the downward pressure on PRME stock.
• Investors might be cautious about the timeline for the initial clinical data from Phase 1/2 trials in CGD expected in 2025, leading to some selling pressure on the stock.

30.08.2024 - PRME Stock was up 5.4%

• PRME stock surged after announcing a partnership with Bristol Myers Squibb worth over $3.5 billion.
• The unveiling of a strategically focused pipeline by Prime Medicine and the efficiency of their Prime Editing Platform likely contributed to investor optimism.
• The collaboration with Bristol Myers Squibb and the promising clinical data expected from their Phase 1/2 trial in 2025 could have further fueled investor enthusiasm for PRME.

24.01.2025 - PRME Stock was down 5.0%

• The decline in PRME stock today could be due to profit-taking by investors following a recent uptrend.
• Despite an upcoming presentation at a healthcare conference, investors might have been underwhelmed by the absence of significant news or partnerships.
• General market sentiment towards biotech companies could be turning pessimistic amid concerns about regulatory challenges and competition in the gene editing sector.
• Investors may be reassessing PRME's growth potential and making adjustments to their positions, influencing today's bearish movement in the stock.

08.04.2025 - PRME Stock was down 5.0%

• PRME reported a Q1 loss and missed revenue estimates, indicating financial underperformance.
• The negative surprises in earnings and revenue could have eroded investor confidence in the company's growth prospects.
• Investors may be concerned about the company's ability to meet future financial targets, leading to a sell-off in the stock.
• The disappointing financial results suggest that PRME may face challenges in the near term, impacting its stock performance negatively.

16.06.2025 - PRME Stock was down 7.7%

• The additional funding of up to $24 million from the Cystic Fibrosis Foundation is positive news for PRME, indicating confidence in their Prime Editing treatments for Cystic Fibrosis.
• However, the market may have reacted bearishly due to concerns about potential dilution from the new funding, leading to profit-taking by investors.
• Investors might also be cautious about the timeline for the development of Prime Editors for Cystic Fibrosis, leading to a short-term bearish sentiment in the stock.

18.02.2025 - PRME Stock was down 7.3%

• Introduction of Prime Medicine's program for treating Alpha-1 Antitrypsin Deficiency (AATD) might have caused investor concerns regarding the company's capability to effectively commercialize this new program.
• Ark Invest, led by Cathie Wood, selling off Prime Medicine shares could have added to the market downturn, indicating a lack of faith in the company's current outlook.
• Market sentiment appears pessimistic following these developments, with investors feeling uncertain about how these updates could affect Prime Medicine's future revenue and growth opportunities.

02.06.2025 - PRME Stock was up 32.4%

• PRME experienced a strong bullish movement today.
• The positive momentum in PRME's stock could be attributed to the overall bullish sentiment in the tech sector.
• Hut 8 Corp's announcement of a significant infrastructure win in Ontario may have boosted investor confidence in the renewable energy sector, positively impacting PRME's stock price.
• Investors may be viewing PRME as a potential beneficiary of the growing interest in renewable energy solutions, driving up the stock price.

22.04.2025 - PRME Stock was up 9.7%

• PRME stock surged after the announcement of promising clinical data for PM359, indicating a swift restoration of DHR positivity in Chronic Granulomatous Disease patients.
• The Phase 1/2 trial results for PM359, showcasing the effectiveness of Prime Editing technology, bolstered investor confidence and uplifted the stock price.
• By focusing on genetic liver diseases and cystic fibrosis, along with favorable clinical trial outcomes, Prime Medicine's strategic realignment contributed to the optimistic sentiment surrounding the company's stock.
• The market's positive response reflects a growing belief in Prime Medicine's innovative gene editing approach and its potential to address unmet medical needs across various genetic disorders.

29.04.2025 - PRME Stock was up 5.3%

• Prime Medicine's participation in upcoming investor conferences may have sparked investor interest and confidence in the company's future prospects.
• The overall positive sentiment in the biotech sector, highlighted by recent industry developments, could have positively influenced PRME's stock price.
• Investors might be optimistic about Prime Medicine's innovative approach to genetic therapies, leading to increased buying activity and driving the stock higher.

20.04.2025 - PRME Stock was down 5.4%

• The bearish movement in PRME's stock could be attributed to the lack of immediate market confidence following the announcement of strategic restructuring and leadership transition within the company.
• Despite the positive clinical data showcasing the efficacy of PM359 in treating Chronic Granulomatous Disease, investors may be cautious due to uncertainties surrounding the company's future direction.
• The shift in analyst sentiment towards other companies in the biotech sector, such as MongoDB (NASDAQ: MDB), could have also influenced overall market sentiment, impacting PRME's stock negatively.
• Investors might be waiting for more concrete developments and regulatory milestones before regaining confidence in PRME's long-term growth potential, leading to the bearish market movement today.